Get the Stockscreener App
2.93
2.09%
0.06
Vistagen Therapeutics Inc stock is traded at $2.93, with a volume of 279.43K.
It is up +2.09% in the last 24 hours and down -2.66% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$2.87
Open:
$2.88
24h Volume:
279.43K
Relative Volume:
1.09
Market Cap:
$84.57M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.1828
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-1.35%
1M Performance:
-2.66%
6M Performance:
-18.61%
1Y Performance:
-39.15%
1-Day Range:
$2.81
$2.99
1-Week Range:
$2.7201
$3.02
52-Week Range:
$2.22
$5.74
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.93 | 84.57M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50 Day Moving AverageHere's Why - MarketBeat
Vistagen CEO to Present Corporate Strategy at TD Cowen Healthcare Conference | VTGN Stock News - StockTitan
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire
Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
VistaGen’s Earnings Call: Progress and Challenges - TipRanks
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlight - GuruFocus.com
VistaGen Reports Q3 2025 Financial Results and Updates - TipRanks
Vistagen Reports Q3 Earnings and Pipeline Progress - TipRanks
Vistagen advances Phase 3 SAD trials with 2025 data readout target - MSN
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - sharewise
Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss - Investing.com
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result - Yahoo Finance
Vistagen Therapeutics (VTGN) Projected to Post Earnings on Tuesday - MarketBeat
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Marketscreener.com
USPTO grants patent to Vistagen’s neuropathic pain treatment - Yahoo Finance
Q3 Earnings Preview: Vistagen to Reveal Latest Progress on Breakthrough Pherine Treatments - StockTitan
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - sharewise
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain -February 05, 2025 at 08:38 am EST - Marketscreener.com
Vistagen secures patent for non-opioid pain treatment By Investing.com - Investing.com UK
Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin - StockTitan
Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Expands By 46.2% - MarketBeat
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen reports positive outcomes from Phase IIA cancer cachexia trial - Yahoo Finance
Vistagen reports promising PH284 nasal spray study By Investing.com - Investing.com Canada
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - sharewise
Vistagen reports promising PH284 nasal spray study - Investing.com
Vistagen's Cancer Cachexia Nasal Spray Shows 71% Hunger Improvement in Phase 2A Trial Success - StockTitan
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Geode Capital Management LLC - Defense World
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - sharewise
HighTower Advisors LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India
VTGN stock touches 52-week low at $2.38 amid market challenges By Investing.com - Investing.com South Africa
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):